Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06213090 · ClinicalTrials.gov registry record
Patterns of Neurodevelopmental Disorders
A clinical trial of Autism Spectrum Disorder and Epilepsy, sponsored by Richard Frye.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT06213090: Recruiting study of Autism Spectrum Disorder and Epilepsy, sponsored by Richard Frye.
NCT06213090 is a study of Autism Spectrum Disorder and Epilepsy that is actively recruiting participants, run by Richard Frye. The registered enrollment target is 1,000 participants, above the 131-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (663% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06213090, a study of Autism Spectrum Disorder and Epilepsy, is actively recruiting participants, sponsored by Richard Frye.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to systematically evaluate the results of medical investigations to identify symptom and biological patterns and common etiologies of neurodevelopmental disorders.
Primary Outcome
It is unknown if a specific set of biological abnormalities contribute to the formation of many types of neurodevelopmental disorders. The study is intended to identify the relationship between biological abnormalities and neurodevelopmental disorders. The chart will be reviewed for medical diagnoses other than the primary neurodevelopmental disorders.
Conditions Studied
Study Locations (1)
Arizona
- Rossignol Medical Center - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2030-12-31 |
What NCT06213090 shows while recruiting
NCT06213090 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 131-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (663% higher).
The record links to 8 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT06213090 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06213090 about?
NCT06213090 is a clinical study titled "Patterns of Neurodevelopmental Disorders". The purpose of this study is to systematically evaluate the results of medical investigations to identify symptom and biological patterns and common etiologies of neurodevelopmental disorders.
What is the current status of trial NCT06213090?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-02-01. Estimated completion is 2030-12-31.
What conditions does trial NCT06213090 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Epilepsy, Down Syndrome, Neurodevelopmental Disorders, Mitochondrial Encephalomyopathies.
Who is sponsoring clinical trial NCT06213090?
This trial is sponsored by Richard Frye, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06213090 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06213090's enrollment target sits among peer trials
1,000 3rd of 224 higher than 221 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design
RECRUITING · Early Phase 1
-
Cannabidiol (CBD) in Adults With ASD
RECRUITING · Phase 1
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI